How to Finance a California Cannabis Business Acquisition: Seller Financing, Earnouts, and Banking Limits
Financing the purchase of a California cannabis business can be more complicated than financing an acquisition in other industries. Buyers and sellers may agree on valuation and key business terms only to discover that the financing structure creates regulatory, banking, collateral, or closing issues.
Because conventional lending remains limited for cannabis businesses, parties frequently consider seller financing, private lending, earnouts, or a combination of funding sources. These arrangements may bridge funding or valuation gaps but introduce distinct legal and practical risks.
The parties should address financing early in the transaction process, including during the letter of intent (LOI) or term sheet stage. The financing structure can affect the form of the acquisition, regulatory disclosures, collateral, closing mechanics, tax considerations, and post-closing risk. Buyers and sellers should therefore avoid locking in payment terms or financing assumptions before evaluating how the proposed funding structure works with the transaction and applicable cannabis regulations.
Financing arrangements may also create their own regulatory consequences. Rights granted to a lender, seller, investor, or other financing party may trigger California Department of Cannabis Control (DCC) disclosure obligations or, depending on the authority granted, cause that party to qualify as an owner.
Why Financing a California Cannabis Acquisition Requires Regulatory Planning
California permits licensed commercial cannabis activity under state law, but the federal treatment of cannabis continues to evolve.[1] At the time of this writing, adult-use commercial cannabis remains federally prohibited, while the 2026 federal rescheduling framework has created a potential pathway for qualifying state-licensed medicinal cannabis businesses to participate in a federally recognized framework if they satisfy applicable federal requirements. The scope and practical impact of these developments remain subject to ongoing federal regulatory proceedings, including potential changes that could further affect the treatment of adult-use cannabis. Regardless of future developments, rescheduling does not automatically make conventional acquisition financing available to California cannabis businesses or eliminate existing regulatory and compliance considerations.[2]
Despite the evolving federal framework, many California cannabis businesses still face limited access to conventional acquisition financing. Some maintain bank accounts and relationships with financial institutions that serve the industry, but those relationships do not necessarily include acquisition loans or other traditional financing products. Banks and institutional lenders may decline cannabis transactions, impose additional underwriting requirements, or limit the transactions they will support. Buyers therefore often turn to seller financing, private lending, investor capital, or a combination of funding sources.
Cannabis acquisition financing can also create DCC disclosure obligations. A lender to the licensed cannabis business generally qualifies as a financial interest holder unless an exclusion applies. Financing provided to a buyer or acquisition vehicle requires a more transaction-specific analysis based on the flow of funds, repayment obligations, economic interests, collateral, and contractual rights.
The DCC also looks beyond the label “lender.” If financing documents grant authority to manage, direct, or control the licensed business, the financing party may qualify as an owner. For example, default provisions that allow a lender to control staffing, inventory, banking, compliance decisions, or other material operations may create ownership consequences even though the agreement characterizes the party only as a creditor.
Buyers and sellers should therefore analyze financing documents as part of the overall transaction structure—not after the purchase agreement has already been negotiated.
How Seller Financing Works in a Cannabis Business Acquisition
In a seller-financed acquisition, the seller allows the buyer to pay part of the purchase price over time. The buyer typically makes a down payment at closing and executes a promissory note for the balance.
Buyers and sellers often use seller financing to bridge the gap between the agreed purchase price and the cash available at closing. For the seller, however, deferring part of the purchase price means assuming post-closing credit risk.
Seller financing effectively leaves the seller invested in the buyer’s post-closing performance. The seller therefore should evaluate not only the interest rate and repayment schedule, but also the buyer’s capitalization, projected cash flow, senior financing, collateral available to secure the note, and the seller’s practical remedies if the buyer defaults.
Key seller-financing terms include:
- Principal, down payment, interest, and maturity.
- Payment schedule and prepayment rights.
- Events of default and cure periods.
- Collateral, lien priority, and subordination.
- Default remedies.
- Rights to offset note payments against indemnification claims.
The parties typically document seller financing through a promissory note and may secure the seller’s payment rights with specified collateral. Depending on the transaction, the parties may also use a security agreement, guaranty, UCC financing statement, or subordination agreement.
The note, purchase agreement, and security documents should use consistent provisions governing payment, default, cure rights, indemnification offsets, acceleration, and remedies. Conflicting provisions can create post-closing disputes.
Practical example: If the buyer discovers an undisclosed tax liability after closing, the purchase agreement may permit the buyer to offset the resulting indemnification claim against note payments. The promissory note should recognize that right and specify whether disputed amounts may be withheld while the claim is resolved.
The parties should determine whether the financing is subject to California usury, finance-lender licensing, or commercial-financing disclosure requirements. The analysis may depend on whether the arrangement is a bona fide credit sale or a loan or forbearance, the identity of the financing party, the amount financed, and any applicable exemption.[3]
How Cannabis Regulations Affect Seller Remedies After Default
Default remedies involving a licensed cannabis business cannot be evaluated solely under ordinary commercial principles. A seller may seek the right to foreclose on collateral or retake equity following a default.
Practical example: A seller may hold a security interest in equipment, intellectual property, receivables, or the buyer’s equity interests. A default does not, however, permit the seller to take possession of cannabis inventory, resume licensed operations, or exercise voting control without first addressing applicable licensing and disclosure requirements.
Depending on the remedy, enforcement may require DCC or local disclosure, approval, or new licensure. A contractual right to foreclose or retake equity does not itself authorize a creditor to assume ownership, management, voting, or operational control of a licensed cannabis business. Security documents should identify the collateral subject to enforcement and the regulatory conditions a creditor must satisfy before exercising particular remedies.
Seller financing and private acquisition financing require more than a promissory note. Manzuri Law regularly advises California cannabis buyers, sellers, investors, and operators on financing structures, collateral, regulatory disclosures, and transaction documents. Our attorneys help clients identify financing terms that may affect ownership, control, or closing and coordinate those issues with the broader acquisition strategy.
Using Earnouts to Bridge Valuation Gaps in Cannabis Acquisitions
An earnout makes a portion of the purchase price contingent on future performance. Buyers and sellers often use earnouts when they agree on the business opportunity but disagree about current value or the likelihood of future growth.
For example, a seller may expect a newly opened dispensary or planned expansion to materially increase revenue, while the buyer may be unwilling to pay today for performance that has not yet occurred. An earnout can bridge that valuation gap by making additional consideration payable only if agreed performance targets are achieved.
Earnout disputes often arise over accounting methods, expense classifications, shared-cost allocations, financial reporting, and operating decisions that affect the selected performance metric.
The agreement should address the buyer’s discretion to change staffing, pricing, marketing, product mix, vendors, operating hours, or other business practices during the earnout period. It should also state whether the buyer must operate consistently with past practice, pursue the earnout target, or refrain from taking actions primarily intended to avoid payment.
The purchase agreement should define the performance metric, permitted accounting adjustments, reporting requirements, payment schedule, inspection rights, dispute procedures, and the buyer’s operating obligations during the earnout period. Terms such as “profit,” “revenue,” or “EBITDA” should include transaction-specific definitions rather than relying on general accounting terminology.
Practical example: If an earnout is based on store-level EBITDA, the agreement should state whether corporate overhead, management fees, legal expenses, and costs associated with opening another location may be allocated to that store. Otherwise, those allocations may materially reduce the earnout even if store revenue increases.
Earnouts can also create cannabis-specific regulatory issues that do not arise in ordinary M&A transactions. The parties should determine whether the earnout creates a reportable financial interest under DCC regulations. A seller entitled to receive 10 percent or more of the licensed business’s profits may qualify as a financial interest holder, while an earnout based on revenue or another metric requires a fact-specific analysis.
The agreement should also give the seller sufficient information rights to verify the earnout without granting operational authority that could cause the seller to qualify as an owner.
How Cannabis Banking Restrictions Can Affect Acquisition Closing
Securing financing does not necessarily solve the closing mechanics. Buyers should confirm early that their bank, investors, lenders, and proposed escrow holder can actually process the contemplated transaction.
Cannabis banking restrictions can affect escrow availability, acquisition wire transfers, source-of-funds review, and closing timelines.
Buyers should be prepared to document the source and movement of acquisition funds for banks, escrow providers, regulators, and other closing participants.
Before setting the closing date, the buyer should confirm that its bank will process the proposed transaction and that the escrow holder can accept and disburse the funds. The parties should account for any additional compliance review in the closing timeline.
Practical example: If the purchase price consists of buyer funds, investor capital, and seller financing, the escrow holder may require documentation for each source before closing. The parties should not assume that providing wire instructions on the scheduled closing date will be sufficient.
How Financing Terms Affect the Cannabis Acquisition Structure
Negotiate financing terms as part of the acquisition structure, not as a separate workstream. Each financing method creates different risks. Seller financing leaves the seller with post-closing credit exposure; earnouts tie a portion of the purchase price to future performance and operating covenants; and private financing may create additional DCC disclosure or control issues.
Promissory notes, security agreements, earnout provisions, guarantees, escrow instructions, and the purchase agreement must therefore work together. The documents should not grant payment, enforcement, voting, management, or control rights that conflict with the parties’ regulatory obligations or the agreed closing structure.
This becomes particularly important when signing, regulatory approval, and final closing occur on different dates. The documents should state when financing obligations become effective, when funds are deposited or released, when interest begins to accrue, who bears carrying costs, and what happens if regulatory approval is delayed or denied.
How Buyers and Sellers Should Plan Cannabis Acquisition Financing
Buyers and sellers should treat acquisition financing as part of the transaction strategy, not merely as a question of how the buyer will fund the purchase price. Financing terms can affect regulatory disclosures, closing mechanics, post-closing obligations, and how the parties allocate risk. Seller financing, earnouts, and private lending can help complete a transaction, but their terms must align with the acquisition structure and the regulatory environment in which the business operates.
Before finalizing the purchase agreement, the parties should confirm funding and escrow mechanics, disclosure requirements, collateral, payment terms, and lawful default remedies.
A well-structured financing strategy can help keep a cannabis acquisition on track while allocating post-closing risk appropriately. Manzuri Law advises clients on California cannabis M&A transactions, acquisition financing, seller notes, earnouts, regulatory diligence, and closing strategy. Our team works with buyers and sellers to structure financing terms that support the transaction’s economics while accounting for California cannabis regulatory requirements.
Call Manzuri Law at 310 912-2960 or contact the firm online to discuss a proposed cannabis business transaction.